<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852761</url>
  </required_header>
  <id_info>
    <org_study_id>114569</org_study_id>
    <secondary_id>U0280-402</secondary_id>
    <nct_id>NCT00852761</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis</brief_title>
  <official_title>A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the efficacy and safety of two different forms of a
      topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted to obtain efficacy and tolerability data for two clobetasol
      propionate therapies in the treatment of plaque-type psoriasis. Subjects will be randomized
      to only one of the two therapies for treatment throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>At Least a One Grade Improvement for the Target Psoriasis Lesion on the Elbow or Knee (Psoriasis Grading Scale)</measure>
    <time_frame>Baseline to day 15</time_frame>
    <description>Number of participants who achieved a minimum 1-grade improvement in elbow and/or knee lesion using the Psoriasis Grading Scale for Target Lesion Score: 0 = No evidence of scaling, erythema, or elevation. 1 = Minimal; occasional scale, faint erythema, slight elevation. 2 = Mild; fine scales, light red color, slight elevation. 3 = Moderate; coarse scales, moderate red coloration and elevation . 4 = Marked; thick scale, bright red coloration, marked elevation. 5 = Severe; very thick tenacious scale predominates, dusky to deep red coloration, very marked elevation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>At Least 1 Grade Improvement Psoriasis Grading Scale</measure>
    <time_frame>Baseline, days 3 and 8</time_frame>
    <description>Number of participants who achieve a minimum one grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.
The scale is the same as used for the primary outcome (0 through 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At Least a 2 Grade Improvement Psoriasis Grading Scale</measure>
    <time_frame>Baseline, days 3, 8, 15</time_frame>
    <description>Number of participants who achieve a minimum two grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.
The scale is the same as used for the primary outcome (0 through 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At Least a 3 Grade Improvement Psoriasis Grading Scale</measure>
    <time_frame>Baseline, days 3, 8, 15</time_frame>
    <description>Number of participants who achieve a minimum of three grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.
The scale is the same as used for the primary outcome (0 through 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At Least 1 Grade Improvement in the Psoriasis Global Assessment</measure>
    <time_frame>Baseline, days 3, 8, 15</time_frame>
    <description>Number of participants who acheive at least a 1 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At Least a 2 Grade Improvement in the Psoriasis Global Assessment</measure>
    <time_frame>Baseline, days 3, 8, 15</time_frame>
    <description>Number of participants who acheive at least a 2 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At Least a 3 Grade Improvement in the Psoriasis Global Assessment</measure>
    <time_frame>Baseline, days 3, 8, 15</time_frame>
    <description>Number of participants who acheive at least a 3 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At Least 1 Grade Improvement in Subject's Global Assessment</measure>
    <time_frame>Baseline, days 3, 8, 15</time_frame>
    <description>Number of participants who achieve treatment success (minimum one grade improvement or more) in their elbow and/or knee target lesion as defined by the Subject's Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At Least a 2 Grade Improvement in Subject's Global Assessment</measure>
    <time_frame>Baseline, days 3, 8, 15</time_frame>
    <description>Number of participants who achieve treatment success (minimum two grade improvement or more) in their elbow and/or knee target lesion as defined by the Subject's Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At Least a 3 Grade Improvement in Subject's Global Assessment</measure>
    <time_frame>Baseline, days 3, 8, 15</time_frame>
    <description>Number of participants who achieve treatment success (minimum three grade improvement or more) in their elbow and/or knee target lesion as defined by the Subject's Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change in Psoriasis Grading Scale</measure>
    <time_frame>Baseline, Days 3, 8, 15</time_frame>
    <description>Median improvement in elbow and/or knee lesion using the Psoriasis Grading Scale for Target Lesion Score: 0 = No evidence of scaling, erythema, or elevation. 1 = Minimal; occasional scale, faint erythema, slight elevation. 2 = Mild; fine scales, light red color, slight elevation. 3 = Moderate; coarse scales, moderate red coloration and elevation . 4 = Marked; thick scale, bright red coloration, marked elevation. 5 = Severe; very thick tenacious scale predominates, dusky to deep red coloration, very marked elevation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Quality of Life - Symptoms and Feelings</measure>
    <time_frame>Baseline, Days 3, 8, 15</time_frame>
    <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 1 and 2. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Quality of Life - Daily Activities</measure>
    <time_frame>Baseline, Days 3, 8, 15</time_frame>
    <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 3 and 4. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Quality of Life - Leisure</measure>
    <time_frame>Baseline, Days 3, 8, 15</time_frame>
    <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 5 and 6. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Quality of Life - Work and School</measure>
    <time_frame>Baseline, Days 3, 8, 15</time_frame>
    <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 7. Score range from 0 to 3. A higher score denotes a more impaired quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Quality of Life - Personal Relationships</measure>
    <time_frame>Baseline, Days 3, 8, 15</time_frame>
    <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 8 and 9. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Quality of Life - Treatment</measure>
    <time_frame>Baseline, Days 3, 8, 15</time_frame>
    <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for question 10. Score range from 0 to 3. A higher score denotes a more impaired quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dermatology Life Quality Index (DLQI) Score</measure>
    <time_frame>Baseline, Days 3, 8, 15</time_frame>
    <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for all questions. Score range from 0 to 30. A higher score denotes a more impaired quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) Categories</measure>
    <time_frame>Days 3, 8, 15</time_frame>
    <description>Number of participants who indicated one of the following for total DLQI: 0-1 No effect on the patient's life; 2-5 Small effect on the patient's life; 6-10 Moderate effect on the patient's life; 11-20 Very large effect on the patient's life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Plaque-Type Psoriasis</condition>
  <arm_group>
    <arm_group_label>Olux-E Foam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olux-E (clobetasol propionate 0.05%) foam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clobex lotion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olux-E Foam</intervention_name>
    <description>Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.</description>
    <arm_group_label>Olux-E Foam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobex lotion</intervention_name>
    <description>Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15</description>
    <arm_group_label>Clobex lotion</arm_group_label>
    <other_name>clobetasol lotion</other_name>
    <other_name>Clobex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body surface area (BSA) affected with psoriasis between 4% and 20% .

          -  Target lesion of at least 2 cmÂ² on the elbow and/or knee, with a score of 2 or 3 on
             the Psoriasis Grading Scale for Target Lesion.

          -  Elbow and/or knee plaque-type psoriasis with a Psoriasis Global Assessment of mild or
             moderate (2 or 3).

          -  Definitive diagnosis of elbow and/or knee plaque-type psoriasis.

          -  Capable of understanding and willing to provide a signed and dated written voluntary
             informed consent (and any local or national authorization requirements) before any
             protocol-specific procedures were performed.

          -  Male or female, 18 years of age or older at the time that the consent form was signed.

          -  Able to complete the study and comply with study instructions.

          -  Female subjects of childbearing potential must have had a negative pregnancy test.
             Sexually active women of childbearing potential participating in the study must have
             been using a medically acceptable form of contraception.

        Exclusion Criteria:

          -  Use of any emollient applied to psoriasis plaques treated with the study medication
             during the study.

          -  Other serious skin disorder or any chronic medical condition that is not well
             controlled.

          -  Female subjects who are pregnant, trying to become pregnant or lactating.

          -  Any major illness within 30 days prior to the baseline visit.

          -  Received any investigational drug or treatment within 30 days of the baseline visit or
             who are scheduled to receive an investigational drug or treatment other than the study
             products during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences Department of Dermatology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2009</study_first_submitted>
  <study_first_submitted_qc>February 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2009</study_first_posted>
  <results_first_submitted>November 4, 2010</results_first_submitted>
  <results_first_submitted_qc>September 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 4, 2011</results_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Clinical research center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Olux-E Foam</title>
          <description>Olux-E (Clobetasol propionate 0.05 percent) foam. Administered twice daily to the elbow and/or knees, morning and evening, after washing with a mild cleanser.</description>
        </group>
        <group group_id="P2">
          <title>Clobex Lotion</title>
          <description>Clobex (Clobetasol propionate 0.05 percent) lotion. Administered twice daily to the elbow and/or knees, morning and evening, after washing with a mild cleanser.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olux-E Foam</title>
          <description>Olux-E (Clobetasol propionate 0.05 percent) foam. Administered twice daily to the elbow and/or knees, morning and evening, after washing with a mild cleanser.</description>
        </group>
        <group group_id="B2">
          <title>Clobex Lotion</title>
          <description>Clobex (Clobetasol propionate 0.05 percent) lotion. Administered twice daily to the elbow and/or knees, morning and evening, after washing with a mild cleanser.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.2" spread="11.7"/>
                    <measurement group_id="B2" value="48.6" spread="13"/>
                    <measurement group_id="B3" value="48.4" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body mass index (BMI) is a measure of body fat based on height and weight that applies to adult men and women and is measured in kg/m^2.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="6.4"/>
                    <measurement group_id="B2" value="30.0" spread="8.8"/>
                    <measurement group_id="B3" value="30.6" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>At Least a One Grade Improvement for the Target Psoriasis Lesion on the Elbow or Knee (Psoriasis Grading Scale)</title>
        <description>Number of participants who achieved a minimum 1-grade improvement in elbow and/or knee lesion using the Psoriasis Grading Scale for Target Lesion Score: 0 = No evidence of scaling, erythema, or elevation. 1 = Minimal; occasional scale, faint erythema, slight elevation. 2 = Mild; fine scales, light red color, slight elevation. 3 = Moderate; coarse scales, moderate red coloration and elevation . 4 = Marked; thick scale, bright red coloration, marked elevation. 5 = Severe; very thick tenacious scale predominates, dusky to deep red coloration, very marked elevation.</description>
        <time_frame>Baseline to day 15</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>At Least a One Grade Improvement for the Target Psoriasis Lesion on the Elbow or Knee (Psoriasis Grading Scale)</title>
          <description>Number of participants who achieved a minimum 1-grade improvement in elbow and/or knee lesion using the Psoriasis Grading Scale for Target Lesion Score: 0 = No evidence of scaling, erythema, or elevation. 1 = Minimal; occasional scale, faint erythema, slight elevation. 2 = Mild; fine scales, light red color, slight elevation. 3 = Moderate; coarse scales, moderate red coloration and elevation . 4 = Marked; thick scale, bright red coloration, marked elevation. 5 = Severe; very thick tenacious scale predominates, dusky to deep red coloration, very marked elevation.</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>At Least 1 Grade Improvement Psoriasis Grading Scale</title>
        <description>Number of participants who achieve a minimum one grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.
The scale is the same as used for the primary outcome (0 through 5).</description>
        <time_frame>Baseline, days 3 and 8</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>At Least 1 Grade Improvement Psoriasis Grading Scale</title>
          <description>Number of participants who achieve a minimum one grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.
The scale is the same as used for the primary outcome (0 through 5).</description>
          <population>Intent to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7298</p_value>
            <p_value_desc>This is the result for the Day 3 analysis.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <p_value_desc>This is the result for the Day 8 analysis.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>At Least a 2 Grade Improvement Psoriasis Grading Scale</title>
        <description>Number of participants who achieve a minimum two grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.
The scale is the same as used for the primary outcome (0 through 5).</description>
        <time_frame>Baseline, days 3, 8, 15</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>At Least a 2 Grade Improvement Psoriasis Grading Scale</title>
          <description>Number of participants who achieve a minimum two grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.
The scale is the same as used for the primary outcome (0 through 5).</description>
          <population>Intent to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7298</p_value>
            <p_value_desc>This is the result for the Day 3 analysis.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0060</p_value>
            <p_value_desc>This is the result for the Day 8 analysis.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0060</p_value>
            <p_value_desc>This is the result for the Day 15 analysis.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>At Least a 3 Grade Improvement Psoriasis Grading Scale</title>
        <description>Number of participants who achieve a minimum of three grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.
The scale is the same as used for the primary outcome (0 through 5).</description>
        <time_frame>Baseline, days 3, 8, 15</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>At Least a 3 Grade Improvement Psoriasis Grading Scale</title>
          <description>Number of participants who achieve a minimum of three grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.
The scale is the same as used for the primary outcome (0 through 5).</description>
          <population>Intent to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0332</p_value>
            <p_value_desc>Data apply to Day 15.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>At Least 1 Grade Improvement in the Psoriasis Global Assessment</title>
        <description>Number of participants who acheive at least a 1 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.</description>
        <time_frame>Baseline, days 3, 8, 15</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>At Least 1 Grade Improvement in the Psoriasis Global Assessment</title>
          <description>Number of participants who acheive at least a 1 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.</description>
          <population>Intent to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>At Least a 2 Grade Improvement in the Psoriasis Global Assessment</title>
        <description>Number of participants who acheive at least a 2 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.</description>
        <time_frame>Baseline, days 3, 8, 15</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>At Least a 2 Grade Improvement in the Psoriasis Global Assessment</title>
          <description>Number of participants who acheive at least a 2 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.</description>
          <population>Intent to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3101</p_value>
            <p_value_desc>This is the result for the Day 3 analysis.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7242</p_value>
            <p_value_desc>This is the result for the Day 8 analysis.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0135</p_value>
            <p_value_desc>This is the p value for day 15</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>At Least a 3 Grade Improvement in the Psoriasis Global Assessment</title>
        <description>Number of participants who acheive at least a 3 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.</description>
        <time_frame>Baseline, days 3, 8, 15</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>At Least a 3 Grade Improvement in the Psoriasis Global Assessment</title>
          <description>Number of participants who acheive at least a 3 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.</description>
          <population>Intent to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>At Least 1 Grade Improvement in Subjectâs Global Assessment</title>
        <description>Number of participants who achieve treatment success (minimum one grade improvement or more) in their elbow and/or knee target lesion as defined by the Subjectâs Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.</description>
        <time_frame>Baseline, days 3, 8, 15</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>At Least 1 Grade Improvement in Subjectâs Global Assessment</title>
          <description>Number of participants who achieve treatment success (minimum one grade improvement or more) in their elbow and/or knee target lesion as defined by the Subjectâs Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.</description>
          <population>Intent to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1449</p_value>
            <p_value_desc>P value at day 15.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1634</p_value>
            <p_value_desc>P value at day 3.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5454</p_value>
            <p_value_desc>P value at day 8.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>At Least a 2 Grade Improvement in Subject's Global Assessment</title>
        <description>Number of participants who achieve treatment success (minimum two grade improvement or more) in their elbow and/or knee target lesion as defined by the Subject's Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.</description>
        <time_frame>Baseline, days 3, 8, 15</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>At Least a 2 Grade Improvement in Subject's Global Assessment</title>
          <description>Number of participants who achieve treatment success (minimum two grade improvement or more) in their elbow and/or knee target lesion as defined by the Subject's Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.</description>
          <population>Intent to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6715</p_value>
            <p_value_desc>This is the p value for day 15.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7242</p_value>
            <p_value_desc>This is the p value for day 8.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6715</p_value>
            <p_value_desc>This is the p value for day 3.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>At Least a 3 Grade Improvement in Subject's Global Assessment</title>
        <description>Number of participants who achieve treatment success (minimum three grade improvement or more) in their elbow and/or knee target lesion as defined by the Subject's Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.</description>
        <time_frame>Baseline, days 3, 8, 15</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>At Least a 3 Grade Improvement in Subject's Global Assessment</title>
          <description>Number of participants who achieve treatment success (minimum three grade improvement or more) in their elbow and/or knee target lesion as defined by the Subject's Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.</description>
          <population>Intent to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4858</p_value>
            <p_value_desc>P value on day 8.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3001</p_value>
            <p_value_desc>P value on day 15.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change in Psoriasis Grading Scale</title>
        <description>Median improvement in elbow and/or knee lesion using the Psoriasis Grading Scale for Target Lesion Score: 0 = No evidence of scaling, erythema, or elevation. 1 = Minimal; occasional scale, faint erythema, slight elevation. 2 = Mild; fine scales, light red color, slight elevation. 3 = Moderate; coarse scales, moderate red coloration and elevation . 4 = Marked; thick scale, bright red coloration, marked elevation. 5 = Severe; very thick tenacious scale predominates, dusky to deep red coloration, very marked elevation.</description>
        <time_frame>Baseline, Days 3, 8, 15</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in Psoriasis Grading Scale</title>
          <description>Median improvement in elbow and/or knee lesion using the Psoriasis Grading Scale for Target Lesion Score: 0 = No evidence of scaling, erythema, or elevation. 1 = Minimal; occasional scale, faint erythema, slight elevation. 2 = Mild; fine scales, light red color, slight elevation. 3 = Moderate; coarse scales, moderate red coloration and elevation . 4 = Marked; thick scale, bright red coloration, marked elevation. 5 = Severe; very thick tenacious scale predominates, dusky to deep red coloration, very marked elevation.</description>
          <population>ITT</population>
          <units>unites on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-1" upper_limit="0"/>
                    <measurement group_id="O2" value="-1" lower_limit="-1" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-2" upper_limit="-1"/>
                    <measurement group_id="O2" value="-2" lower_limit="-2" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-2" upper_limit="-1"/>
                    <measurement group_id="O2" value="-2" lower_limit="-2" upper_limit="-2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Quality of Life - Symptoms and Feelings</title>
        <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 1 and 2. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
        <time_frame>Baseline, Days 3, 8, 15</time_frame>
        <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Quality of Life - Symptoms and Feelings</title>
          <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 1 and 2. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
          <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, n=16, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="1.12"/>
                    <measurement group_id="O2" value="2.41" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.2"/>
                    <measurement group_id="O2" value="1.35" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, n=17, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.95"/>
                    <measurement group_id="O2" value="0.94" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Quality of Life - Daily Activities</title>
        <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 3 and 4. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
        <time_frame>Baseline, Days 3, 8, 15</time_frame>
        <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Quality of Life - Daily Activities</title>
          <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 3 and 4. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
          <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, n=16, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.96"/>
                    <measurement group_id="O2" value="1.41" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.94"/>
                    <measurement group_id="O2" value="0.88" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, n=17, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="1.07"/>
                    <measurement group_id="O2" value="0.82" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Quality of Life - Leisure</title>
        <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 5 and 6. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
        <time_frame>Baseline, Days 3, 8, 15</time_frame>
        <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Quality of Life - Leisure</title>
          <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 5 and 6. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
          <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, n=16, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.97"/>
                    <measurement group_id="O2" value="0.94" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.94"/>
                    <measurement group_id="O2" value="0.41" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, n=17, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="1.0"/>
                    <measurement group_id="O2" value="0.24" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Quality of Life - Work and School</title>
        <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 7. Score range from 0 to 3. A higher score denotes a more impaired quality of life</description>
        <time_frame>Baseline, Days 3, 8, 15</time_frame>
        <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Quality of Life - Work and School</title>
          <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 7. Score range from 0 to 3. A higher score denotes a more impaired quality of life</description>
          <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, n=15, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.35"/>
                    <measurement group_id="O2" value="0.24" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=16, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.25"/>
                    <measurement group_id="O2" value="0.12" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, n=17, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.24"/>
                    <measurement group_id="O2" value="0.06" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Quality of Life - Personal Relationships</title>
        <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 8 and 9. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
        <time_frame>Baseline, Days 3, 8, 15</time_frame>
        <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Quality of Life - Personal Relationships</title>
          <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for questions 8 and 9. Score range from 0 to 6. A higher score denotes a more impaired quality of life</description>
          <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, n=15, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.49"/>
                    <measurement group_id="O2" value="0.41" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=16, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.45"/>
                    <measurement group_id="O2" value="0.29" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, n=17, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.53"/>
                    <measurement group_id="O2" value="0.12" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Quality of Life - Treatment</title>
        <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for question 10. Score range from 0 to 3. A higher score denotes a more impaired quality of life</description>
        <time_frame>Baseline, Days 3, 8, 15</time_frame>
        <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Quality of Life - Treatment</title>
          <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for question 10. Score range from 0 to 3. A higher score denotes a more impaired quality of life</description>
          <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, n=16, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.60"/>
                    <measurement group_id="O2" value="0.35" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.59"/>
                    <measurement group_id="O2" value="0.24" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, n=17, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.39"/>
                    <measurement group_id="O2" value="0.24" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Dermatology Life Quality Index (DLQI) Score</title>
        <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for all questions. Score range from 0 to 30. A higher score denotes a more impaired quality of life</description>
        <time_frame>Baseline, Days 3, 8, 15</time_frame>
        <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dermatology Life Quality Index (DLQI) Score</title>
          <description>Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.
Sum of scores for all questions. Score range from 0 to 30. A higher score denotes a more impaired quality of life</description>
          <population>ITT (Note: some subjects did not complete the survey at all timepoints; however, all data available was analyzed.)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="2.82"/>
                    <measurement group_id="O2" value="5.76" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread="3.44"/>
                    <measurement group_id="O2" value="3.29" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="3.64"/>
                    <measurement group_id="O2" value="2.41" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Life Quality Index (DLQI) Categories</title>
        <description>Number of participants who indicated one of the following for total DLQI: 0-1 No effect on the patient's life; 2-5 Small effect on the patient's life; 6-10 Moderate effect on the patient's life; 11-20 Very large effect on the patient's life.</description>
        <time_frame>Days 3, 8, 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olux-E Foam</title>
            <description>Olux-E (clobetasol propionate 0.05%) foam</description>
          </group>
          <group group_id="O2">
            <title>Clobex Lotion</title>
            <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Life Quality Index (DLQI) Categories</title>
          <description>Number of participants who indicated one of the following for total DLQI: 0-1 No effect on the patient's life; 2-5 Small effect on the patient's life; 6-10 Moderate effect on the patient's life; 11-20 Very large effect on the patient's life.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3 Score 0 -1 No effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Score 2- 5 Small effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Score 6- 10 Moderate effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Score 11- 20 Very large effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Score 0 -1 No effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Score 2- 5 Small effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Score 6- 10 Moderate effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Score 11- 20 Very large effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Score 0 -1 No effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Score 2- 5 Small effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Score 6- 10 Moderate effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Score 11- 20 Very large effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through Day 15.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Olux-E Foam</title>
          <description>Olux-E (clobetasol propionate 0.05%) foam</description>
        </group>
        <group group_id="E2">
          <title>Clobex Lotion</title>
          <description>Clobex (clobetasol propionate 0.05%) lotion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA, Version 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hpertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

